Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

NCT04454450 | Active Not Recruiting

• 1 other identifier: 20-212
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The researchers are doing this study to find out whether the researchers can combine information provided by PET/MRI scans with information from tests on blood and tissue samples to develop a very detailed description (profile) of high-grade serous ovarian carcinoma (HGSOC), which could improve our ability to treat this disease. The study researchers will use computers to analyze the combined results of the imaging tests and the genetic and immune system tests on the tumor samples. The study researchers think that this information will help them more accurately predict the way tumors respond to treatment, which may improve their ability to individualize treatments for this disease.

Conditions

Ovarian Cancer; High Grade Ovarian Serous

Keywords

FIGO stage IIIC-IV; PET radiotracer; 20-212

Outcome Measures

Primary Outcomes (1)

• Comparison between radiologist tumor segmentation

  Radiologist-defined tumor volumes will be used to train and validate a machine learning algorithm for generating segmentations. The data will be split into 70%-30% of training and test sets, respectively. The comparisons will be performed on a slice-by-slice and lesion-bylesion basis, which should ensure sufficient numbers of examples for testing.

  1 year

Study Arms (2)

Imaged prior to primary debulking surgery

EXPERIMENTAL

Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).

Diagnostic Test: PET/MRI; Diagnostic Test: Contrast enhanced CT

Imaged pre/postneoadjuvant chemotherapy (NACT)

EXPERIMENTAL

In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).

Diagnostic Test: PET/MRI; Diagnostic Test: Contrast enhanced CT

Interventions

Contrast enhanced CT DIAGNOSTIC_TEST

Standard of care contrast enhanced CT

Imaged pre/postneoadjuvant chemotherapy (NACT); Imaged prior to primary debulking surgery

PET/MRI DIAGNOSTIC_TEST

Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.

Imaged pre/postneoadjuvant chemotherapy (NACT); Imaged prior to primary debulking surgery

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Ovarian Cancer
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥ 18 years of age or older
• Histologically confirmed or clinically suspected FIGO stage IIIC-IV HGSOC
• Signed consent to MSK Institutional tissue banking protocol IRB# 06-107 and signed or planned to sign IRB# 12-245, and planned to undergo multi-region tissue collection \[under the above IRB protocols\] and plan to undergo subsequent tissue analysis under biospecimen IRB# 15-200.
• Staging standard-of-care contrast-enhanced CT of abdomen and pelvis (+/-chest) available in picture archiving and communication system (PACS) that was obtained at our institution as a part of standard-of-care work-up or submitted for from the outside
• Plasma glucose ≤200 mg/dL
• Negative pregnancy test, if a patient is of child-bearing potential

You may not qualify if:

• Known allergy to gadolinium-based contrast medium requiring premedication or known adverse reactions to gadolinium-based contrast medium.
• Known history of impaired renal function, with documented eGFR \<30 within 30 days prior to PET/MRI.
• Patients who cannot give valid informed consent because of general medical or physical condition, or physiologic status unrelated to presence of ovarian cancer
• Patients who are unwilling or unable to undergo PET/MRI including patients with absolute or relative contraindications to MRI including breast tissue expanders, cardiac pacemakers and defibrillators, non MRI-compatible aneurysm clips, neurostimulators, programmable CSF shunts, vascular stents, claustrophobia, or inability to lie flat for the duration of the examination.
• Patients with metallic hardware, implant, or device in the abdomen or pelvis that might distort the local magnetic field and compromise image quality.
• Radiotherapy to the abdomen or pelvis within 12 months of the screening visit.
• Subjects with a current diagnosis of ovarian cancer other than HGSOC
• Patients with known synchronous primary endometrial cancer or past history of endometrial cancer.
• Patients who have received prior chemotherapy for any abdominal or pelvic tumor. Patients may have received prior adjuvant chemotherapy for breast cancer.
• With the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with excluded known concurrent malignancy.
• Unresolved bowel obstruction.
• History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study.
• Absence of any target lesions ( ≥1-2 cm) in the pelvis (right adnexa, left adnexa, infra-colic omentum, pelvic peritoneum) visible on staging standard-of-care CE-CT and accessible for tissue sampling at laparoscopy and/or primary/ interval debulking surgery.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (1)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Viktoriya Paroder, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2020
• First Posted: July 1, 2020
• Study Start: June 22, 2020
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: March 6, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

US (1)